This week in drug discovery (30 Sept – 4 Oct)
News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer.
The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in cystic fibrosis, paediatric brain cancer, and rare diseases.
The top stories:
£3m boost to paediatric brain cancer research
Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours.
£3m accelerates new drugs for lung infections in cystic fibrosis
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding.
FDA awards grants to seven clinical trials for orphan products
The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases.
New therapy for Huntington’s disease gets £35 million boost
Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF).
NK:IO progresses ovarian cancer natural killer therapy
Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million including additional funding from UK Innovation Science and Seed Fund (UKI2S).
